Insider Purchases: Inside the Buy
Tag: Biotech
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Insider Intel: What CEOs Are Buying (And What They Hope You Won’t Notice)
CEOs and top execs are putting their money where their mouth is—but should you follow their lead? From Moderna's biotech bet to Permian's big energy play, this week's insider moves reveal patterns worth watching. Dive into the details and spot the next market trend before it hits the headlines.